-
Hi-Tech Pharmacal Acquires Nystatin Oral Suspension ANDA
Monday, March 21, 2011 - 8:04am | 97Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that it has acquired the rights to the Abbreviated New Drug Application (ANDA) for Nystatin Oral suspension from Bausch + Lomb, the global eye health company for an undisclosed upfront payment and a future royalty. Nystatin oral suspension is...
-
Jefferies Updates On VRX
Monday, March 21, 2011 - 7:51am | 91Jefferies has issued an update on Valeant Pharmaceuticals (NYSE: VRX). According to Jefferies, "In this note, we provide our periodic review of Valeant's overall business. We see no major flaws and continue to expect upside to numbers from both the existing business as well as future accretive...
-
Citi Comments On Allergan's Over Active Bladder Data
Monday, March 21, 2011 - 7:41am | 185In a report published by Citi, Allergan (NYSE: AGN) Presented Positive Results for its First Botox Phase III Trial in Neurogenic Overactive Bladder (OAB) at the European Association of Urology (EAU) meeting in Vienna. Citi said that the positive data was expected since AGN filed its supplementary...
-
A Peek Into The Market Before The Trading Starts
Monday, March 21, 2011 - 7:36am | 420Pre-open movers US stock futures are higher this morning, after AT&T (NYSE: T) announced its plans to buy T-Mobile USA for around $39 billion. Futures for the Dow Jones Industrial Average surged 105 points to 11,904.00, while those for the S&P 500 stock index climbed 13.60 points to 1,287....
-
Jefferies Maintains Buy on ViroPharma (VPHM)
Monday, March 21, 2011 - 7:35am | 79Jefferies is out with its report today on ViroPharma (NASDAQ: VPHM), maintaining Buy. In a note to clients, Jefferies writes, "The European Medicines Agency's CHMP disclosed it gave a positive opinion to Cinryze for hereditary angioedema treatment, and we expect a decision on European approval in...
-
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal and VPRIV
Monday, March 21, 2011 - 7:28am | 84Shire plc (Nasdaq: SHPGY) presented new data for Replagal (agalsidase alfa) in patients with Fabry disease, and VPRIV (velaglucerase alfa for injection) in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' (ACMG) Annual Clinical Genetics Meeting, held in...
-
Morgan Stanley Reports Mylan Seeking FDA Approval Of Generic Lipitor In June 2011 For Watson Pharmaceuticals
Monday, March 21, 2011 - 7:21am | 130In a report published by Morgan Stanley, Mylan is seeking FDA approval of generic Lipitor in June 2011 for Watson Pharmaceuticals (NYSE: WPI). Morgan Stanley said that Mylan is suing FDA to deny Ranbaxy's 180 days of marketing exclusivity on generic Lipitor. “If FDA denies Ranbaxy's exclusivity,...
-
Morgan Stanley Reports Early Generic Lipitor Risk Explained And Quantified For Pfizer
Monday, March 21, 2011 - 7:17am | 106In a report published by Morgan Stanley, Pfizer's (NYSE: PFE) early generic Lipitor risk is explained and quantified. Morgan Stanley said that Mylan filed a lawsuit to compel FDA to act on generic Lipitor. “Mylan believes that FDA should deny Ranbaxy's exclusivity if FDA invoked its Application...
-
FDA Assigns PDUFA Date for Shire's FIRAZYR for the Treatment of Acute Attacks of Hereditary Angioedema
Monday, March 21, 2011 - 7:17am | 155Shire plc (NASDAQ: SHPGY) today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of...
-
Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Cash (SLXP, PRX, CPD, HITK)
Monday, March 21, 2011 - 1:09am | 146Below are the top small-cap drugs-generic stocks on the NYSE and the NASDAQ in terms of cash. Salix Pharmaceuticals Ltd (NASDAQ: SLXP) had $518.03 million in total cash and $323.49 million in total debt for the latest quarter. Pharmaceutical Companies (NYSE: PRX) had $246.54 million in total...
-
Top Trade Ideas for the Week of March 21
Saturday, March 19, 2011 - 5:36pm | 1904( click to enlarge ) The Technical daily chart shows an exhaustion move, where the price had penetrated the $12.70 level confluence with 50-day moving average, but failed to hold above it. The trend direction in short term is now bearish. The medium-term trend outlook for the stock is neutral...
-
Market Both Popped Then Faded on News 03-18-2011
Friday, March 18, 2011 - 7:14pm | 866Cusick's Corner Stocks rose earlier on the day after G7 central banks agreed to coordinate efforts in the currency markets to help weaken the Japanese yen. Japan continues to struggle with their crisis – however, there was not much focus on the news that Japan's nuclear alert level rose from 4 to...
-
Forest Laboratories Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Clinical Data
Friday, March 18, 2011 - 2:59pm | 95Forest Laboratories, Inc. (NYSE: FRX) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with Forest's previously announced acquisition of all outstanding shares of common stock of, and certain outstanding...
-
Biotech Sector Snapshot HIV Drug Development
Friday, March 18, 2011 - 2:13pm | 2042Point Roberts, WA - March 18, 2011- Investorideas.com releases an industry snapshot on HIV- AIDS drug makers and recent data that suggests the HIV virus has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats...
-
Options Brief: Jazz Pharmaceuticals, Inc. (JAZZ)
Friday, March 18, 2011 - 1:54pm | 85Shares of Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) are higher on the session by 2.73%, trading at $29.35. Overall call volume is now running at 2.34x the daily average, with 66% of all calls traded being purchases on the offer. 1,458 contracts have traded on the session so far. Jazz...